课题基金 / 基金详情

DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS

DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
强力霉素治疗仅使用孕激素的避孕者的出血
批准号:
7086287
负责人:
DAVID Fitzgerald ARCHER
金额:
$31.08万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-27 至 2008-06-30

项目摘要

项目成果

DAVID Fitzgerald ARCHER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):临床上,使用仅孕激素避孕的女性中有很高比例发生突破性出血,导致生活方式受损,并导致对该避孕方法的依从性降低。 需要一种有效的、低成本的、易于适应的治疗方法来减少单用避孕药的出血和点滴出血。 与许多其他炎症性疾病一样,具有突破性出血[BTB]和斑点的女性子宫内膜的分子环境含有异常高水平的促炎细胞因子(TNF-α和IL-1 β)和异常高水平的蛋白酶(基质金属蛋白酶[MMPs]和中性粒细胞弹性蛋白酶),其阻止正常组织修复。 多西环素[DOX]是一种廉价的,FDA批准的抗生素,抑制MMP,TACE活性,并减少NO的合成。DOX在牙周和溃疡性疾病的动物模型和临床研究中的治疗益处是由于其对MMPs的抑制,而不是其抗生素作用。 我们预计使用DOX不会降低避孕效果。 我们建议临床评价DOX治疗孕激素避孕药诱导的BTB和斑点,并生化表征DOX治疗患者中发生的子宫内膜分子生物学变化。如果成功,DOX治疗可能成为治疗这种和可能影响生殖道组织的其他炎症性疾病的重要辅助手段。
英文摘要
DESCRIPTION (provided by applicant): Clinically, a high percentage of women using progestin-only contraception experience breakthrough bleeding spotting that causes impaired lifestyle and results in decreased compliance with this contraceptive method. There is a need for an effective, low-cost, easily adapted treatment to reduce the bleeding and spotting in progestin only contraceptives. The molecular environment of the endometrium of women with breakthrough bleeding [BTB] and spotting, like many other inflammatory disorders, contains abnormally high levels of pro-inflammatory cytokines (TNF-alpha and IL-1beta)and abnormally high levels of proteases (matrix metalloproteinases [MMPs] and neutrophil elastase), which prevent normal tissue repair. Doxycycline [DOX] is an inexpensive, FDA approved antibiotic that inhibits MMPs, TACE activity, and reduces NO synthesis. The therapeutic benefit of DOX in animal models and clinical studies of periodontal and ulcerative diseases is due to its inhibition of MMPs, not to its antibiotic effect. We do not anticipate any reduction in contraceptive efficacy with the use of DOX. We propose to clinically evaluate DOX treatment of progestin-only contraceptive induced BTB and spotting, and to biochemically characterize the endometrial molecular biologic changes that occur in DOX treated patients. If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant.
多西环素对使用左炔诺孕酮释放皮下植入物的女性血清和子宫内膜 MMP-2、MMP-9 和 TIMP-1 水平的影响。
DOI: 10.1016/j.contraception.2008.12.010
发表时间: 2009
期刊: Contraception
影响因子: 2.9
作者: [Zhao,Shumei, Choksuchat,Chainarong, Zhao,Yueqin, Ballagh,SusanA, Kovalevsky,GeorgeA, Archer,DavidF]
通讯作者: Archer,DavidF
Levonorgestrel effects on serum androgens, sex hormone-binding globulin levels, hair shaft diameter, and sexual function.
左炔诺孕酮对血清雄激素、性激素结合球蛋白水平、毛干直径和性功能的影响。
DOI: 10.1016/j.fertnstert.2008.12.095
发表时间: 2010
期刊: Fertility and sterility
影响因子: 6.7
作者: [Kovalevsky,George, Ballagh,SusanA, Stanczyk,FrankZ, Lee,Jennifer, Cooper,Joann, Archer,DavidF]
通讯作者: Archer,DavidF
Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells.
黄体酮、左炔诺孕酮和醋酸甲羟孕酮对人子宫内膜内皮细胞凋亡的影响。
DOI: 10.1016/j.contraception.2008.08.008
发表时间: 2009
期刊: Contraception
影响因子: 2.9
作者: [Choksuchat,Chainarong, Zhao,Shumei, Deutch,ToddD, Kimble,ThomasD, Archer,DavidF]
通讯作者: Archer,DavidF
Retraction notice to Doxycycline Alters the Expression of Matrix Metalloproteases in the Endometrial Cells Exposed to Ovarian Steroids and Pro-inflammatory Cytokine JRI 73/2 (April 2017);118-129.
强力霉素的撤回通知会改变暴露于卵巢类固醇和促炎细胞因子 JRI 73/2 的子宫内膜细胞中基质金属蛋白酶的表达(2017 年 4 月);118-129。
DOI: 10.1016/j.jri.2017.11.002
发表时间: 2018
期刊: Journal of reproductive immunology
影响因子: 3.4
作者: [Li,Rongxiu, Luo,Xiaoping, Archer,DavidF, Chegini,Nasser]
通讯作者: Chegini,Nasser
On Demand Oral Contraception for Obese Women
  • 批准号:
    10699536
  • 项目类别:
  • 资助金额:
    $38.24万
  • 财政年份:
    2023
  • 负责人:
    DAVID Fitzgerald ARCHER
  • 依托单位:
Novel On Demand Female Oral Contraceptive
  • 批准号:
    10155056
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    DAVID Fitzgerald ARCHER
  • 依托单位:
DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
  • 批准号:
    6560253
  • 项目类别:
  • 资助金额:
    $24.47万
  • 财政年份:
    2002
  • 负责人:
    DAVID Fitzgerald ARCHER
  • 依托单位:
DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
  • 批准号:
    6921381
  • 项目类别:
  • 资助金额:
    $31.92万
  • 财政年份:
    2002
  • 负责人:
    DAVID Fitzgerald ARCHER
  • 依托单位:
海外基金